Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Innovative Purdue Deal, Infinity Finds Shelter From The Storm

This article was originally published in The Pink Sheet Daily

Executive Summary

In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.

You may also be interested in...



Infinity Extends R&D Collaboration With Mundipharma, Gets Another $50 Million For PI3K Program

Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf

Related Content

Topics

UsernamePublicRestriction

Register

PS067047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel